New drug tested for rare kidney conditions
NCT ID NCT05083364
Summary
This early-stage study tested the safety and effects of an experimental drug called ARO-C3. It involved 62 healthy volunteers and patients with rare kidney diseases (C3G and IgAN). The goal was to see how the body processes the drug and determine safe dose levels for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Auckland, 1010, New Zealand
-
Research Site 1
Camperdown, New South Wales, 2050, Australia
-
Research Site 1
Gamcheon, Busan, 49267, South Korea
-
Research Site 2
Clayton, Victoria, 3168, Australia
-
Research Site 2
Tbilisi, 0112, Georgia
-
Research Site 2
Cologne, 50937, Germany
-
Research Site 2
Haeundae, Busan, 48108, South Korea
-
Research Site 2
Bangkok, 10400, Thailand
-
Research Site 3
Concord, New South Wales, 2139, Australia
-
Research Site 3
Daegu, Daegu, 42601, South Korea
-
Research Site 3
Chiang Mai, 50200, Thailand
-
Research Site 4
Erlangen, 91054, Germany
-
Research Site 4
Goyang-si, Gyeonggi-do, 10444, South Korea
-
Research Site 4
Oxford, OX3 7LE, United Kingdom
-
Research Site 6
Soeul, 03722, South Korea
-
Research Site 8
Soeul, 05030, South Korea
Conditions
Explore the condition pages connected to this study.